Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 181a-2 (MIR181A2)
- Target
- MIR181A2
- Molecular classification
- MicroRNA, Non-coding RNA, Regulatory RNA, Other
01
Overview
MicroRNA 181a-2 (MIR181A2) is a non-coding RNA classified as a microRNA, functioning as a post-transcriptional regulator of gene expression. MIR181A2 is part of the miR-181 family, regulating cell fate, differentiation, apoptosis, mitochondrial function, and immune homeostasis. It acts as an oncogene in several cancers, especially gastric and hepatic carcinomas, through repression of target mRNAs such as CAPRIN1 and MYLK, thereby promoting proliferation, survival, and metastasis. Its altered expression is also implicated in neurodegenerative disorders and embryonic development. MIR181A2 is under investigation as a therapeutic target and biomarker; however, due to its pleiotropic effects, therapeutic development faces significant specificity and safety challenges.
- Other names
- hsa-mir-181a-2hsa-mir-181aMIRN181AMIRN181A2mir-181a-2mir-181amicroRNA-181a-2
02
Mechanism of action
Therapeutic strategies are experimental and include antisense oligonucleotides or inhibitors to suppress miR-181a-2 function, aiming to restore tumor suppressor activity or reverse chemoresistance. Drug resistance mechanisms may be modulated via target gene interactions (e.g., TIMP3, MYLK).
03
Biological functions
Post-transcriptional regulation of gene expressionCell differentiationCell proliferationCell invasion and migrationApoptosis regulationMitochondrial functionEmbryonic developmentImmune modulation
04
Disease associations
Cancer (e.g., gastric carcinoma, hepatocellular carcinoma, leukemia, glioma)Neurodegenerative diseases (e.g., Parkinson’s disease)Other (role in embryonic development, immune-related diseases)
05
Safety considerations
Targeting microRNAs may impact multiple pathways due to their broad regulatory roles, raising the risk of off-target effects and unintended modulation of physiological gene expression.Potential impact on immune system and embryonic development needs consideration in therapeutic strategies
06
Interacting drugs
No approved drugs directly target MIR181A2. Research suggests modulation by drugs such as doxorubicin (resistance influenced via downstream targets), but no pharmacological agents specifically target MIR181A2 in practice
07
Biomarkers
Overexpression of miR-181a-2 is a biomarker of poor prognosis in certain cancers (e.g., gastric cancer)Potential biomarker for response to chemotherapeutics and for stratification of certain tumors
Beyond the preview
Go deeper on MicroRNA 181a-2 (MIR181A2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 181a-2 (MIR181A2).